<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514344</url>
  </required_header>
  <id_info>
    <org_study_id>IRIS</org_study_id>
    <nct_id>NCT01514344</nct_id>
  </id_info>
  <brief_title>Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma</brief_title>
  <acronym>IRIS</acronym>
  <official_title>Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andres J. M. Ferreri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, monocentric, open label study to assess safety and activity of intralesional
      Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary data suggest intralesional rituximab is able to revert resistance to systemic
      rituximab in patients with CD20+ indolent lymphoma of the conjunctiva, and the addition of
      autologous serum seems to exhibit a synergistic effect on tumor regression. These two main
      aspects will be assessed in this trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of safety</measure>
    <time_frame>During experimental treatment (within 7 months from trial registration)</time_frame>
    <description>assessment of safety of intralesional rituximab in terms of incidence of &gt;/= G4 adverse events during the experimental treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessment of activity</measure>
    <time_frame>at the end of experimental treatment (at 7th month from trial registration)</time_frame>
    <description>assessment of activity of intralesional rituximab in terms of overall partial and complete response and duration of response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma</condition>
  <arm_group>
    <arm_group_label>intralesional rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intralesional rituximab</intervention_name>
    <description>10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months</description>
    <arm_group_label>intralesional rituximab</arm_group_label>
    <other_name>Intraconjunctival rituximab; mabthera, anti-CD20 therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>supplemental autologous serum</intervention_name>
    <description>patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum</description>
    <arm_group_label>intralesional rituximab</arm_group_label>
    <other_name>autologous serum supplementation; complement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological diagnosis of CD20+ B cell lymphoma subtypes: marginal zone lymphoma,
             grade 1-2 follicular lymphoma, plasmocytic lymphoma, small lymphocyte lymphoma

          -  conjunctival localization alone (1EA stage; mono- or bilateral)

          -  at least one measurable lesion

          -  age &gt;/= 18 years

          -  ECOG-PS &lt;/=3

          -  HIV 1-2 negativity

          -  at least one previous treatment (antibiotic or rituximab)

        Exclusion Criteria:

          -  concomitant conventional (chemo-, radiation, immuno-), experimental (antibiotic) or
             corticosteroid anticancer therapy

          -  known allergy to rituximab

          -  systemic symptoms

          -  concurrent diagnosis of pemphigus

          -  postsurgical conjunctival scars
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Raffaele Scientific Institute, Milano, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <phone>+39022643</phone>
    <phone_ext>7649</phone_ext>
    <email>ferreri.andres@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Govi, MD</last_name>
    <phone>+39022643</phone>
    <phone_ext>7612</phone_ext>
    <email>govi.silvia@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <phone>+39022643</phone>
      <phone_ext>7649</phone_ext>
      <email>ferreri.andres@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Govi, MD</last_name>
      <phone>+39022643</phone>
      <phone_ext>7612</phone_ext>
      <email>govi.silvia@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Andres J. M. Ferreri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>OAL</keyword>
  <keyword>MALT</keyword>
  <keyword>conjunctiva</keyword>
  <keyword>indolent</keyword>
  <keyword>CD20+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

